Bio

Kevin has over 30 years’ experience working in the healthcare sector, principally with pharmaceutical, biotechnology and business consultancy companies. He has been involved in the successful divestment and acquisition of many businesses, acting as advisor to major pharmaceutical and biotechnology companies. Successful transactions he led whilst at PharmaVentures included the sale of 2 Sanofi research sites to Covance, divesting Dow Pharmaceuticals API manufacturing division to Dr Reddy’s Ltd, the sale of manufacturing businesses from UCB to Aesica, the divestment of Merck’s research site in Newhouse, Scotland to BioCity and in 2012 the divestment of Zentiva’s (a Sanofi Group Company) Hlohovec plant to Wood Pharma Holding. In the last five years his divestments have resulted in the successful transfer of over 3,700 jobs to new owners and significant value creation for clients. Kevin also has extensive experience in licensing of research compounds, technologies, IP and pharmaceutical products. During his career Kevin has held senior positions in pharmaceutical research, alliance management, business development and transactions. He has worked at Hoechst (Sanofi) , Quintiles, Roche Pharmaceuticals, Inpharmatica and PharmaVentures, where until August 2012 he was Head of Transactions.